Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Altimmune (ALT) over the last 16 years, with Q3 2025 value amounting to $524000.0.

  • Altimmune's Change in Receivables rose 1300000.0% to $524000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $417000.0, marking a year-over-year increase of 19287.31%. This contributed to the annual value of -$567000.0 for FY2024, which is 16044.78% down from last year.
  • Altimmune's Change in Receivables amounted to $524000.0 in Q3 2025, which was up 1300000.0% from -$186000.0 recorded in Q2 2025.
  • Altimmune's Change in Receivables' 5-year high stood at $741000.0 during Q3 2023, with a 5-year trough of -$3.1 million in Q3 2021.
  • Moreover, its 5-year median value for Change in Receivables was $3000.0 (2022), whereas its average is -$198157.9.
  • In the last 5 years, Altimmune's Change in Receivables crashed by 400000.0% in 2023 and then surged by 1300000.0% in 2025.
  • Quarter analysis of 5 years shows Altimmune's Change in Receivables stood at -$1.1 million in 2021, then soared by 59.83% to -$460000.0 in 2022, then surged by 150.87% to $234000.0 in 2023, then tumbled by 50.43% to $116000.0 in 2024, then soared by 351.72% to $524000.0 in 2025.
  • Its Change in Receivables was $524000.0 in Q3 2025, compared to -$186000.0 in Q2 2025 and -$37000.0 in Q1 2025.